Saniya Saleem1, Amyn A Malik2,3, Asma Ghulam2, Junaid Ahmed2, Hamidah Hussain3. 1. Global Health Directorate, Indus Health Network, Karachi, Pakistan. saniya.saleem@ghd.ihn.org.pk. 2. Global Health Directorate, Indus Health Network, Karachi, Pakistan. 3. Interactive Research and Development, Karachi, Pakistan.
Abstract
PURPOSE: Health-related quality of life (HRQoL) of pulmonary TB patients has not been assessed in Pakistan. We assessed self-reported HRQoL of pulmonary TB patients in Karachi, Pakistan utilizing the EQ-5D and EQ-VAS prior to, during, and after completion of TB treatment. METHODS: We enrolled 226 pulmonary TB patients in a longitudinal cohort study. Health-utility scores were estimated by the EQ-5D five dimensions and the EQ-Visual Analogue Scale (VAS) at baseline (month 0) and each monthly follow-up visit until treatment completion at month 6. Repeated-measures ANOVA was used to investigate effect of time into treatment on EQ-5D and EQ-VAS scores. RESULTS: EQ-5D health utility and EQ-VAS scores increase with treatment progression. For the enrolled TB patients, the mean EQ-5D utility scores more than doubled from 0.43 to 0.88, p < .001, effect size η2 = 0.40 from treatment initiation to treatment completion. CONCLUSION: Perceived HRQoL of TB patients improves with treatment progression. This can inform targeted treatment plans as well as TB policy and funding for high-burden countries.
PURPOSE: Health-related quality of life (HRQoL) of pulmonary TBpatients has not been assessed in Pakistan. We assessed self-reported HRQoL of pulmonary TBpatients in Karachi, Pakistan utilizing the EQ-5D and EQ-VAS prior to, during, and after completion of TB treatment. METHODS: We enrolled 226 pulmonary TBpatients in a longitudinal cohort study. Health-utility scores were estimated by the EQ-5D five dimensions and the EQ-Visual Analogue Scale (VAS) at baseline (month 0) and each monthly follow-up visit until treatment completion at month 6. Repeated-measures ANOVA was used to investigate effect of time into treatment on EQ-5D and EQ-VAS scores. RESULTS: EQ-5D health utility and EQ-VAS scores increase with treatment progression. For the enrolled TBpatients, the mean EQ-5D utility scores more than doubled from 0.43 to 0.88, p < .001, effect size η2 = 0.40 from treatment initiation to treatment completion. CONCLUSION: Perceived HRQoL of TBpatients improves with treatment progression. This can inform targeted treatment plans as well as TB policy and funding for high-burden countries.
Entities:
Keywords:
EQ-5D; Health-related quality of life; Public health; Tuberculosis
Authors: I-Chan Huang; Constantine Frangakis; Mark J Atkinson; Richard J Willke; Walter L Leite; W Bruce Vogel; Albert W Wu Journal: Health Serv Res Date: 2008-02 Impact factor: 3.402
Authors: Melissa Bauer; Sara Ahmed; Andrea Benedetti; Christina Greenaway; Marek Lalli; Allison Leavens; Dick Menzies; Claudia Vadeboncoeur; Bilkis Vissandjée; Ashley Wynne; Kevin Schwartzman Journal: Health Qual Life Outcomes Date: 2015-05-27 Impact factor: 3.186
Authors: Y Jo; I Gomes; H Shin; A Tucker; L G Ngwira; R E Chaisson; E L Corbett; D W Dowdy Journal: Int J Tuberc Lung Dis Date: 2020-11-01 Impact factor: 2.373
Authors: Ali Ahmed; Muhammad Saqlain; Naila Bashir; Juman Dujaili; Furqan Hashmi; Faizan Mazhar; Amjad Khan; Musarat Jabeen; Ali Blebil; Ahmed Awaisu Journal: Qual Life Res Date: 2021-02-13 Impact factor: 4.147